Revolution Medicines Inc (RVMD) carries a ŷRobot AI score of 46 out of 100. The model's fair value estimate is $181.19, 11.4% below the last close of $204.48. The chart signal reads Sell.
| Metric | RVMD |
|---|---|
| AI score | 46 / 100 |
| Chart signal | Sell |
| Fair value estimate | $181.19 |
| Upside to fair value | -11.4% |
| Previous close | $204.48 |
| P/E | -24.65 |
| Price / sales | 59,381.47 |
| Market cap | $43.93B |
| EPS | -8.34 |
| Revenue growth | -100.3% |
| 1-year price change | 42.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Revolution Medicines Inc (RVMD) at $181.19 against a last close of $204.48, implying 11.4% downside to the model's estimate.
The chart-signal model classifies RVMD as Neutral as of Sep 29, 2026, with a signal score of -0.14 on a -1 to 1 scale.
RVMD scores 46 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
RVMD trades at -24.6 times earnings and 59381.5 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for RVMD reads +3.2% at 30 days, +20.8% at 90 days, and +42.6% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Revolution Medicines Inc's revenue growth is -100.3% and free-cash-flow growth is -30.6% on the latest reported figures.
RVMD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.